THEMATIC REVIEW

Novel targeted therapeutics for MEN2

Sara Redaelli¹, Ivan Plaza-Menacho² and Luca Mologni¹¹School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy²Spanish National Cancer Research Center (CNIO), Madrid, SpainCorrespondence should be addressed to L Mologni: luca.mologni@unimib.itThis paper is part of a thematic review section on 25 Years of *RET* and MEN2. The guest editors for this section were Lois Mulligan and Frank Weber

Abstract

The rearranged during transfection (*RET*) proto-oncogene was recognized as the multiple endocrine neoplasia type 2 (MEN2) causing gene in 1993. Since then, much effort has been put into a clear understanding of its oncogenic signaling, its biochemical function and ways to block its aberrant activation in MEN2 and related cancers. Several small molecules have been designed, developed or redirected as RET inhibitors for the treatment of MEN2 and sporadic MTC. However, current drugs are mostly active against several other kinases, as they were not originally developed for RET. This limits efficacy and poses safety issues. Therefore, there is still much to do to improve targeted MEN2 treatments. New, more potent and selective molecules, or combinatorial strategies may lead to more effective therapies in the near future. Here, we review the rationale for RET targeting in MEN2, the use of currently available drugs and novel preclinical and clinical RET inhibitor candidates.

Key Words

- ▶ cell signaling
- ▶ multiple endocrine neoplasias
- ▶ oncogene
- ▶ thyroid

Endocrine-Related Cancer
(2018) **25**, T53–T68

MEN2: introduction

Mary (fictitious name) is a beautiful and joyful eighteen-year-old girl who enjoys her life. You do not notice anything wrong with her, if not for her slightly too long and slender fingers and limbs. She has multiple endocrine neoplasia type 2 (MEN2) and a marfanoid appearance. However, in a sense, she is lucky: the cause of her disease had been discovered few years before her birth. Now, she is under treatment with a drug that keeps the disease at bay.

MEN2 is a group of hereditary, autosomal dominant syndromes characterized by the occurrence of various endocrine tumors (Schimke 1984). Three MEN2 clinical subtypes are recognized: MEN2A, MEN2B and familial MTC (FMTC). MEN2A patients develop medullary thyroid carcinoma (MTC), pheochromocytoma and parathyroid hyperplasia or adenoma. In contrast, MEN2B patients do not have parathyroid involvement, but often show a number of additional conditions, such as marfanoid

features and mucosal neuromas of the lips and the tongue and gastrointestinal manifestations (Marx 2005, Wells et al. 2013). Moreover, MEN2B is generally more aggressive and occurs earlier in life. FMTC patients only develop MTC; thus, some authors view FMTC as a MEN2A variant without adrenal gland involvement. Clinical management of MEN2 patients includes prophylactic thyroidectomy, periodical biochemical screening for urine catecholamine and epinephrine, as well as serum calcium, calcitonin and parathyroid hormone levels and surgical removal of tumors. The etiology of MEN2 syndrome remained obscure until 1993, when Mulligan and coworkers discovered germline mutations of the *RET* proto-oncogene in MEN2A patients (Mulligan et al. 1993). *RET* is a signaling co-receptor for neurotrophic factors (Ederly et al. 1997). At that time, it was known to be frequently rearranged in papillary thyroid cancers

(PTC), but its involvement in MEN2 and MTC was not yet clear (Grieco *et al.* 1990, Santoro *et al.* 1990). The paper by Mulligan and colleagues opened a new era for specific treatment of these conditions. MEN2A patients carry cysteine-specific mutations in the extracellular domain of RET, that are involved in conformational stability and kinase activity via intramolecular disulfide bridges. These mutations cause covalent dimerization of RET leading to ligand-independent kinase activation (Plaza-Menacho *et al.* 2006, Mologni 2011, Goodman *et al.* 2014). Mutations affecting cysteine 634 account for most cases, with C634W being the most prevalent MEN2A mutation, although other cysteines from the cysteine-rich domain (CRD) have been described (Ito *et al.* 1997). In contrast, the vast majority of MEN2B patients carry a M918T mutation in the catalytic domain of RET. Methionine 918 is located near the kinase activation loop: mutation to threonine causes the opening of the activation loop and induces faster autophosphorylation kinetics (Plaza-Menacho *et al.* 2014). FMTC can be caused by both extra- and intracellular domains mutations, including cysteine substitutions at the CRD and kinase domain-activating mutations. Of particular interest from a pharmacological standpoint are FMTC mutations at the gatekeeper valine, V804, which render the kinase refractory to inhibition by some inhibitors (Carlomagno *et al.* 2004, Mologni *et al.* 2013).

RET signaling in MEN2

Molecular dissection of disease-driving mechanisms is fundamental for the development of precise therapeutics able to target the disease causative process while sparing normal functions on the organism. Perturbation of RET signaling by a series of oncogenic events, i.e. single germline/somatic point mutation, gene rearrangement, overexpression or transcriptional upregulation, is a common hallmark in several human cancers. The understanding of the mechanism of action associated with these oncogenic RET 'variants' is crucial for the development of more accurate (i.e., targeted) and successful therapeutic strategies to treat patients with RET-positive cancers.

Despite clear genotype–phenotype correlations observed in the cancer syndrome MEN2, the molecular mechanisms linking the different sets of RET mutations with their specific clinical subtypes are far from understood. Work from the last two and a half decades on the genetics and cell signaling of the RET proto-oncogene has described two main mechanisms of action for specific

disease-phenotype-associated RET mutations. First, mutations affecting the extracellular cysteine-rich domain (CRD) of RET, associated with MEN2A and FMTC, lead to covalent dimerization and constitutive activation of the receptor (Takahashi *et al.* 1999). The recent elucidation of the structural architecture of RET extracellular domain in complex with GDNF-GFR α 1 showed a composite ligand-binding site, with RET wrapping around the co-receptor/ligand complex (Goodman *et al.* 2007). A GFR α 1-binding hotspot contacts the RET cadherin-like domains, while the CRD contacts both ligand components and makes membrane-proximal homotypic interactions, leading to receptor homodimerization and activation. These CRD-mediated interactions suggest models both for ligand-induced RET activation and for ligand-independent oncogenic dysregulation by MEN2 cysteine mutations (Goodman *et al.* 2007). Second, mutations affecting the intracellular domain of RET, usually associated with FMTC and always with the MEN2B phenotype, transform the receptor into a monomeric ligand-independent oncoprotein (Santoro *et al.* 1995). RET MEN2B variants, in particular RET M918T, show not only an altered catalytic activity but also an altered substrate specificity because they preferentially phosphorylate substrates that, contrary to wild-type RET, are usually preferred by cytoplasmic tyrosine kinases such as FAK (Murakami *et al.* 1999) and SRC (Kato *et al.* 2002, Encinas *et al.* 2004, Plaza-Menacho *et al.* 2011). The transcription factor STAT3 is one such example (Yuan *et al.* 2004). In addition, RET-MEN2B mutants seem to lack dependency on activation loop Y905 for both cells transformation and signaling (Iwashita *et al.* 1996, 1999). One plausible explanation about the molecular basis of the disease spectrum is that a different pattern of receptor autophosphorylation displayed by specific RET mutants connects a different set of phospho-tyrosine-mediated downstream signaling pathways and transcriptional programs with specific clinical phenotypes. Recent biochemical, biophysical and structural evaluation of RET M918T and V804M mutants (both targeting the catalytic domain of RET) revealed increased kinetics of autophosphorylation and a more extended activation loop conformation, giving rise to a better intermolecular substrate compared to RET WT (Plaza-Menacho *et al.* 2014). These data have important implications due to the perturbation of the temporal assembly and specificity of RET signaling complexes. Another interesting observation is that oncogenic RET seems to be heavily internalized and prolonged treatment with specific tyrosine kinase inhibitors (e.g. sorafenib) induced lysosomal degradation

(Plaza-Menacho *et al.* 2007). Interestingly, degradation promoted by tyrosine kinase inhibitor (TKI) was apparently higher for RET C634R (MEN2A) than RET M918T (MEN2B). However, blocking HSP90 activity by 17-AAG induced an equally potent degradation of wild-type RET and MEN2-associated RET mutants (Alfano *et al.* 2010). Altogether these studies highlight the complexity of RET (oncogenic) signaling, in a way that localization of the receptor in specific subcellular compartments, maturation status and the interaction with intracellular and extracellular components are important elements to understand RET function and oncogenic deregulation.

The rationale of a different temporal pattern of receptor activation with specific clinical phenotypes (Plaza-Menacho *et al.* 2006) has been supported by several studies. In cell-based experiments, RET M918T (MEN2B) triggers elevated levels of PI3K activity (Murakami *et al.* 1999) and Jun N-terminal kinase activity JNK (Murakami *et al.* 2002) compared with RET C634R. In addition, RET M918T switches the specificity of the RET tyrosine kinase toward alternative substrates that interact with Crk and Nck (Bocciardi *et al.* 1997). The same applies to the interaction with other SH2- or PTB-containing docking/adaptor proteins. For example, RET M918T (MEN2B) showed both enhanced phosphorylation of Y1062 and association with SHC, compared with RET C634R (MEN2A) mutants, resulting in the higher activation of the RAS/ERK1/2 and the PI3K/AKT signaling pathways (Salvatore *et al.* 2001). Liu and colleagues showed that RET-MEN2B mutants lack phosphorylation at Y1096, directly leading to a decrease in binding of GRB2 to RET, compared with wild-type RET (Liu *et al.* 1996). Transactivation of STAT3 by RET C634R (MEN2A) is required for cellular transformation in a process that is independent of non-receptor tyrosine kinases JAKs and SRC (Schuringa *et al.* 2001). On the contrary, activating point mutations targeting the kinase domain, such as RET Y791F and RET S891A (FMTC) implicate JAKs and SRC kinases in the constitutive activation of STAT3 (Plaza Menacho *et al.* 2005). In another study, oncogenic RET M918T (MEN2B) was shown to interact with and activate STAT3 more strongly than RET C634R (MEN2A) (Yuan *et al.* 2004). In the same line, oncogenic RET enhanced in cells the phosphorylation levels of FAK activation loop Y576/577 phosphorylation compared to wild-type RET, and kinase domain mutants (RET M918T-MEN2B and RET V804M, a FMTC-associated drug-resistant mutant) induced a more robust phosphorylation than mutants targeting the extracellular domain (e.g., RET C634R, MEN2A). Interestingly, this pattern was mirrored by levels of SRC Y416 kinase activation promoted by RET,

indicating a close relationship between levels of RET, FAK, SRC and STAT3 activation (Plaza-Menacho *et al.* 2011).

Taken all together, these studies indicate that specific sets of signaling pathways are connected with specific sets of MEN2-associated RET mutations. A better understanding of the molecular mechanisms underlying this cancer syndrome ultimately will be necessary to design new therapeutic strategies to treat this disease. Combinatorial therapies targeting RET and other important (disease-specific) downstream effectors may be a real alternative to mono-therapies based on TKIs targeting (oncogenic) RET catalytic activity (see below).

Targeted treatments for MEN2/MTC

Approved drugs

The spectacular success of imatinib in chronic myeloid leukemia (CML) patients in early 2000s (Kantarjian *et al.* 2002) indicated that targeted treatment may change a disease history in rationally selected patients. Belonging to the same protein class as the imatinib target ABL1, RET was the next kid on the block. A list of completed and ongoing clinical trials investigating the efficacy of RET inhibitors in familial thyroid cancer is shown in Table 1.

Vandetanib (Caprelsa, ZD6474, Genzyme Corp), an orally available kinase inhibitor active against VEGFR2 and EGFR, was later found to be also a potent RET inhibitor (Carlomagno *et al.* 2002, Wedge *et al.* 2002, Vidal *et al.* 2005). The efficacy and safety of vandetanib in patients with MTC were first evaluated in two phase II studies (Robinson *et al.* 2010, Wells *et al.* 2010). In the trial conducted by Robinson and colleagues, vandetanib administered 100mg/daily which resulted in a partial response (PR) in 16% of the patients and in stable disease (SD) for at least 24 weeks in 53% of the treated cases. Wells and colleagues described the use of 300mg/daily as able to induce a PR in 20% of patients and a SD in 53%, with a median progression-free survival (PFS) of 27.9 months. A large multicenter, randomized placebo-controlled crossover phase III study was conducted in a cohort of 331 patients with hereditary and sporadic forms of MTC (ZETA trial, Wells *et al.* 2012). The patients were randomly divided 2:1 between vandetanib (300mg/daily, $n=231$) or placebo ($n=100$) arms. The predicted median PFS for the vandetanib arm was 30.5 months, significantly higher than the 19.3 months observed for placebo. A PR was observed in 45% patients with a predicted median duration of 22 months, while 42% had SD, yielding a disease control rate of 87%. The analysis showed evidence

Table 1 Clinical trials investigating RET inhibitors in medullary thyroid cancer patients.

Phase	Drug	Dose#	Condition	Outcome*	Reference/ID
II	Vandetanib	100 mg/day	FMTc	16% PR, 53% SD	(39)
II	Vandetanib	300 mg/day	FMTc	20% PR, 53% SD	(40)
III	Vandetanib	300 mg/day	MTC	45% PR, 42% SD	(41)
I/II	Vandetanib	150 mg/m ² /day	MEN2B	44% ORR	(42)
I	Cabozantinib	Dose finding	MTC	29% PR, 41% SD	(45)
III	Cabozantinib	140 mg/day	MTC	28% PR	(46)
II	Sorafenib	400 mg bid	MTC	6% PR, 88% SD	(51)
II	Sorafenib	400 mg bid	MTC/DTC	25% PR, 70% SD	(52)
II	Lenvatinib	24 mg/day	MTC	36% PR	(57)
II	Sunitinib	37.5 mg/day	MTC/DTC	50% PR	(61)
II	Sunitinib	50 mg/day	MTC/DTC/ATC	38% PR, 50% SD	(62)
II	Motesanib	125 mg/day	MTC	2% PR, 81% SD	(74)
II	Fostamatinib	200 mg bid	Multi-histology	50% SD	(79)
I/II	Alectinib	Bid, dose finding	RET-mutated thyroid cancer	n.d.	NCT03131206
I	LOXO-292	Dose finding	MTC	n.d.	NCT03157128
II	Ponatinib	30 mg/day	MTC, previously treated with vandetanib or cabozantinib	100% PD halted for toxicity	NCT01838642
II	Ponatinib	n.a.	RET-mutated cancer	n.d.	NCT02272998
II	Apatinib	500 mg/day	Thyroid cancer	n.d.	NCT03199677
II	Nintedanib	200 mg bid	MTC/DTC	n.d.	NCT01788982
I	Dovitinib + paclitaxel	200 mg/day	Multi-histology	100% SD (RET ^{mut} non-MTC)	(94)
II	Pazopanib	800 mg/day	MTC	14% PR	(98)
I-Ib	RXDX-105	20–350 mg/day	BRAF- or RET-mutated cancer	1 PR	NCT01877811; (99)
I	BLU-667	Dose finding	MTC/other RET-mutated cancer	n.d.	NCT03037385
I	GSK3352589	1–100 mg/day	Healthy subjects	n.d.	NCT03154086
I	GSK3179106	10–200 mg/day	Healthy subjects	n.d.	NCT02798991
I	GSK3179106	5–100 mg/day	Healthy subjects	n.d.	NCT02727283
I/II	Vandetanib + bortezomib	Up to 300 mg qd	MTC	29% PR	NCT00923247
Ib	Semaxanib + paclitaxel	110 mg/m ² on days 1, 15, 18, 22 and 25	Head and neck	100% SD	(141)
I	Vandetanib + everolimus	Starting 100 mg/day	Advanced cancers	n.d.	NCT01582191

#In combination studies, the data refer to the RET inhibitor; *refers to the MTC population only, when the study involved other cancer types (unless specified).

ATC, anaplastic thyroid carcinoma; bid, *bis in die* (twice daily); DTC, differentiated thyroid carcinoma; MTC, medullary thyroid carcinoma; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.

that RET mutation-positive patients had higher benefit than RET-negative ones, although the trend did not reach statistical significance due to the limited number of patients in the latter group. Adverse events (AEs) were observed in more than 30% of patients and included diarrhea, nausea, rash and hypertension. About half (49%) of the patients had a vandetanib-related increase of TSH levels and 8% of cases developed QTc prolongation. Five patients died because of serious side effects. Based on these results, the FDA (in 2011) and the EMA (in 2012) approved the use of vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. More recently, a phase I/II study aimed to assess the drug's safety, tolerance, pharmacokinetic as well as

the antitumor activity in a cohort of 10 adolescents and 6 children affected by MEN2B-associated MTC (Fox et al. 2013). All the patients but one expressed the M918T RET mutation. The tumor size decreased in all the 15 patients carrying the mutation. The overall objective response rate was 44% (7/15 patients; 95% confidence interval (CI): 21–73%) with a decrease in calcitonin level of 59% after one cycle of therapy. However, three children experienced progression after an initial PR.

An alternative to vandetanib is currently represented by cabozantinib (Cometriq, XL-184, Exelixis Inc), a potent inhibitor of MET, VEGFR2/KDR, RET, as well as other receptor tyrosine kinases, such as KIT, AXL and FLT3. In *in vitro* biochemical assays, cabozantinib displays inhibitory activity against both wild-type and mutated

M918T and Y791F RET forms associated with MTC (Yakes *et al.* 2011, Bentzien *et al.* 2013). Cabozantinib received FDA approval in 2012 and EMA approval in 2014 for the treatment of patients with progressive metastatic MTC. The activity of cabozantinib was firstly assessed in a phase I study on 87 patients with different solid tumors, including 37 MTC patients (Kurzrock *et al.* 2010). In the MTC subgroup 29% of cases achieved a PR and 41% had a SD for at least 6 months. The subsequent multicenter, randomized, placebo-controlled phase III EXAM study (Elisei *et al.* 2012) involved 330 patients with histologically confirmed unresectable, locally advanced or metastatic MTC that were randomly assigned 2:1 either to cabozantinib (140 mg/daily) or to placebo. Forty-eight percent patients harbored RET mutations. The PFS observed for the cabozantinib arm was significantly longer than placebo (11 vs 4 months, hazard ratio (HR) 0.28). PR was achieved in 28% of patients with a median duration of response of 14.7 months, while the median overall survival (OS) did not significantly differ in the two arms: 26.6 months under cabozantinib and 21.1 in the placebo group ($P=0.24$). In the subgroups harboring RET mutation, a PR was observed in 34% of cases, PFS was 13.9 months and the OS was 44.3 months (vs 18.9 months in the placebo arm, $P=0.025$). The most frequent AEs of grade 3 and 4 were diarrhea, hand-foot syndrome, fatigue and hypertension.

Investigational drugs

Several small molecules have been designed, developed or repurposed as RET kinase inhibitors during the past decade (reviewed in Phay & Shah 2010, Mologni 2011, Borrello *et al.* 2013, Mologni *et al.* 2017a,b). Some have already been approved for non-MEN2 thyroid cancer and are under investigation for MEN2, others are in advanced clinical development or have been clinically tested in a limited number of patients.

Sorafenib (Nexavar, Bay 43-9006, Bayer Healthcare Pharmaceuticals Inc) is an orally available VEGFR1–3, RET, BRAF and PDGFR inhibitor. Its use in differentiated thyroid carcinoma (DTC) has been approved by the FDA and the EMA in 2013 and 2014, respectively (Brose *et al.* 2014). Sorafenib activity in MTC was assessed in two prospective phase II studies (Lam *et al.* 2010, Ahmed *et al.* 2011). Lam and colleagues enrolled 21 MTC patients observing a PR in 6% of cases and SD in 88%. The PFS was 17.9 months. Similarly, Ahmed and colleagues studied a cohort of 15 MTC: 25% of cases achieved a PR, and the authors reported 100% OS at 12 months. Adverse events

observed upon treatment with sorafenib in MTC patients, as well as in other thyroid cancer types include hand-foot syndrome, diarrhea, skin rash and fatigue. Larger cohorts will have to be evaluated before drawing conclusions on the efficacy of sorafenib in these patients.

Lenvatinib (Lenvima, E7080, Eisai Co Ltd) is an orally available multi-targeted TKI with reported activity against VEGFR 1–3, FGFR 1–4, PDGFR alpha, RET and KIT (Matsui *et al.* 2008, Bruheim *et al.* 2011, Wiegner *et al.* 2014). Lenvatinib has been approved by the EMA and the FDA for the treatment of patients with progressive radioiodine-refractory DTC recurrent or metastatic (Nair *et al.* 2015). The use of lenvatinib in MTC has been explored by Schlumberger and colleagues in a multicenter phase II study involving 59 patients treated with 24 mg/day in 28-day cycles (Schlumberger *et al.* 2016). The primary endpoint of the study was ORR, which was 36% (all PRs). Patients with or without prior VEGFR-targeted treatment responded similarly (35% vs 36% RR, respectively). Median PFS was 9 months and the achieved response was not affected by the RET mutational status.

Among the most advanced investigational compounds, sunitinib (Sutent, SU11248; Pfizer Ltd) has completed phase I and II trials in thyroid cancer (Dawson *et al.* 2008, Carr *et al.* 2010, Atallah *et al.* 2016, Bikas *et al.* 2016, Ravaud *et al.* 2017) and is currently undergoing specific evaluation in RET fusion-positive tumors (NCT02450123). Sunitinib was part of a large indolinone compound collection at SUGEN Inc (later acquired by Pfizer), which was initially developed to block angiogenic kinases belonging to the split tyrosine kinase domain family (VEGFR, FGFR, PDGFR) (Sun *et al.* 1998, 1999, 2000). Later, a few closely related compounds from this series were shown to inhibit RET at submicromolar concentrations *in vitro* and *in vivo* (Kim *et al.* 2006, Mologni *et al.* 2006, Chow & Eckhardt 2007, Jeong *et al.* 2011). Among these, SU11248 showed the best pharmacologic properties and progressed into clinical trials. Thus, although the published anti-RET preclinical data are scarce, and despite the broad multikinase activity of sunitinib, its safety profile is already well established from previous trials for other targets (it is approved for renal-cell carcinoma and imatinib-refractory GIST). This prompted clinical investigation in thyroid cancer patients. Overall, Sutent achieved 20–40% objective responses and 70–80% disease control rate (including SD) in the thyroid cancer patients' population, which is in line with the currently approved drugs. Sunitinib was generally well tolerated in these patients, with mostly grade 1 or 2 treatment-related adverse events. The most frequent

toxicities observed in the different studies were fatigue, hand-foot syndrome, leukopenia and diarrhea, in some cases reaching grade 3–4 severity and leading to treatment discontinuation (about 10%) or dose reduction from the recommended 37.5 to 25 mg/die. One report described cardiac events in 14% of patients, half of whom had a severe episode (Ravaud *et al.* 2017). None of the other studies in thyroid cancer patients reported cardiovascular events; however, sunitinib had been watched for cardiovascular risk in patients with renal-cell carcinoma and gastrointestinal stromal tumors (Chu *et al.* 2007). A KIF5B-RET-positive non-small-cell lung cancer (NSCLC) case was reported with rapid response to sunitinib and clinical improvement after three days of treatment, in a heavily compromised patient (Wu *et al.* 2015). However, treatment was discontinued after 10 weeks for toxicity. Unfortunately, significant toxic effects seem relatively common among patients treated with sunitinib, which likely reflects its lack of selectivity. This may limit its clinical efficacy.

Motesanib (AMG-706, Amgen/Takeda) was originally developed by Amgen as an anti-angiogenic drug targeting VEGFR and c-Kit (Polverino *et al.* 2006). Activity was also noted *in vitro* against RET kinase in the nanomolar range, although with 1-log reduced potency compared to the primary targets. Thus, RET was a clinically interesting off target for motesanib. The compound was highly selective vs a number of other kinases. This may be due to its ability to make contact with small gatekeeper residues, which RET (V804), VEGFR (V916) and c-Kit (T670) have in common. On the other hand, this is a vulnerability, as motesanib is totally inactive against gatekeeper mutants, such as RET V804M (Mologni *et al.* 2013). In further preclinical studies, motesanib inhibited wildtype but not mutant RET C634W and M918T phosphorylation in cells. Consequently, proliferation of cells driven by mutant RET was not affected. However, in animal models, motesanib showed antitumor activity against xenografts carrying a M918T mutant RET (Coxon *et al.* 2012). This apparent contradiction is probably explained by anti-angiogenic effects of the drug. Clinical development of motesanib was later taken up by Takeda. In phase II studies, the drug showed modest activity in MTC (2% PR, 81% SD) as well as in DTC (14% PR, 67% SD) patients (Sherman *et al.* 2008, Schlumberger *et al.* 2009). Moreover, pharmacokinetic analyses indicated that motesanib trough concentrations were lower in MTC compared to DTC patients. The vast majority of patients (88%) experienced AEs, with a significant proportion (38%) of grade 3 AEs (Schlumberger *et al.* 2009). Currently, motesanib is mostly

undergoing clinical evaluation as a VEGFR, PDGFR and c-Kit inhibitor (Raghav & Blumenschein 2011).

Fostamatinib is a multikinase inhibitor prodrug currently investigated as a SYK inhibitor (Bajpai 2009). Also in this case, the compound was inadvertently found to block RET kinase activity (Clemens *et al.* 2009). A recent multi-histology trial evaluated four thyroid cancer patients (papillary and follicular type), two of whom achieved SD as their best response (Park *et al.* 2013). In addition, one of the two patients with pheochromocytoma had durable SD. Although no MTC patient was enrolled, these data may encourage investigation of fostamatinib in MEN2 patients.

Alectinib (Alecensa, CH5424802, Roche/Chugai) is an anaplastic lymphoma kinase (ALK) inhibitor, approved for the treatment of advanced NSCLC refractory to crizotinib (Gadgeel *et al.* 2014). It was subsequently shown to be an effective RET inhibitor *in vitro* and *in vivo* (Kodama *et al.* 2014). Although alectinib is not quite as potent against RET as it is against ALK, the compound is active on most RET mutants tested and shows very good selectivity for RET vs VEGFR, which may be a competitive advantage over competing drugs. Alectinib will soon be tested in *RET*-rearranged NSCLC and *RET*-mutated thyroid cancer patients, in a non-randomized phase I/II study at Dana-Farber Cancer Institute (NCT03131206). A recent study reported objective responses in two of four *RET*-rearranged NSCLC patients (Lin *et al.* 2016a,b). From a clinical standpoint, alectinib has the advantage of already being well characterized. Whether it will show the same spectacular efficacy in RET-positive tumors as observed in ALK-driven disease remains to be ascertained.

Loxo Oncology recently developed a selective RET inhibitor named LOXO-292 with >100× selectivity vs KDR/VEGFR2, which compares favorably with cabozantinib and vandetanib on both wild-type and mutant RET (Brandhuber *et al.* 2016). The molecule shows good oral bioavailability and pharmacokinetics (PK) in animals, as well as high efficacy in RET-dependent tumor models, including xenografts and patient-derived tumor grafts. A multicenter phase I trial in patients with advanced RET fusion-positive NSCLC and MTC is currently recruiting participants (NCT03157128), to define the maximum tolerated dose (MTD).

Ponatinib (Iclusig, AP-24534, Ariad Pharmaceuticals) was developed to circumvent the highly intractable ABL gatekeeper mutant T315I in Philadelphia-positive chronic myeloid leukemia (Zhou *et al.* 2011, Cortes *et al.* 2012). It has been approved for the treatment of adult patients with T315I-positive CML and ALL or patients that have failed

all other TKIs. Most like the V804M/L mutants of RET, substitution of a bulky isoleucine for wild-type threonine in ABL kinase renders the drug-binding site unfit to accommodate imatinib as well as second-generation ABL inhibitors (Quintas-Cardama & Cortes 2008). Through an innovative design, ponatinib was specifically made to overcome the steric impediment provided by the mutant residue, thus making this drug highly active against gatekeeper mutants. Indeed, when ponatinib was shown to potently inhibit RET (De Falco *et al.* 2013, Mologni *et al.* 2013), V804M/L mutants were shown to be effectively blocked. At the time of writing this manuscript, a phase II trial in advanced MTC previously treated with vandetanib and cabozantinib has been terminated prematurely (NCT01838642), and a new study was announced to open soon. Only 2 patients could be evaluated in the closed trial (both RET mutation positive), with no objective response (best response: PD). Other phase II, open-label trials in advanced NSCLC with RET translocations are currently recruiting patients (NCT01813734 and NCT01935336). Primary outcome will be overall response rate at 2 and 5 years, respectively. A new basket trial is recruiting patients with any refractory metastatic tumor carrying alterations in ponatinib targets, including RET (NCT02272998). As ponatinib is affected by significant systemic toxicity, which led to early termination of the first trial, its use may be confined to second or third lines of TKI therapy. Alternatively, dose reduction might be explored (Pinilla-Ibarz *et al.* 2013).

Apatinib is a potent VEGFR-2 inhibitor, which also targets PDGFR- β , c-Src, c-Kit and RET (Scott *et al.* 2015). Recently, it was shown to block invasion by RET fusion-positive lung cancer cells *in vitro* (Lin *et al.* 2016a,b). Since apatinib was already in advanced clinical phases of development (Li *et al.* 2016) as an anti-angiogenic drug, it is now under evaluation in metastatic refractory thyroid cancer, including MTC (NCT03199677) as well as in RET-positive NSCLC (NCT02540824).

Nintedanib (Vargatef, Ofef, BIBF 1120, Boehringer Ingelheim) is an anti-angiogenic multikinase inhibitor targeting VEGFRs, PDGFRs and FGFRs (Capdevila *et al.* 2014) used to treat idiopathic pulmonary fibrosis and lung cancer. In a recent retrospective analysis, the drug was reported to have achieved one complete response (CR) and one SD in two RET-rearranged NSCLC patients (Gautschi *et al.* 2017). Interestingly, according to the same study, ponatinib obtained only stabilization in two treated patients, while alectinib ($n=2$) failed. However, numbers are too small to draw any conclusions. Cabozantinib, vandetanib and sunitinib, for which at least 10 patients

were evaluable, achieved 37, 18 and 22% overall responses, respectively (Gautschi *et al.* 2017), in line with observations in thyroid cancer. No data are available for the use of nintedanib in MEN2 or MTC, yet. However, a new phase II study is ongoing in MTC or DTC patients progressing after first-line therapy (NCT01788982).

Dovitinib (TKI258, CHIR258, Novartis) is another multi-targeted angiokinase inhibitor with anti-RET activity. It was investigated in a series of patients with various cancers (not MTC) and found to have sustained antitumor activity in two patients carrying a RET^{G691S} germline variant (Quintela-Fandino *et al.* 2014). Interestingly, the same variant had previously been found in early-onset MEN2A patients and considered as a genetic modifier, cooperating with known oncogenic mutations to confer high penetrance an activating, oncogenic mutation (Robledo *et al.* 2003).

Pazopanib (Votrient, GW786034B, GlaxoSmithKline) is a VEGFR1/2/3, PDGFR α/β , and c-Kit inhibitor used for the treatment of renal-cell carcinoma (Sonpavde & Hutson 2007). It was tested in thyroid cancer patients on the basis of its anti-angiogenic properties, first in DTC (Bible *et al.* 2010) then in MTC (Bible *et al.* 2014). While in DTC patients the authors recorded 49% confirmed PRs, the results in MTC were less encouraging, with only 5/35 (14%) responding patients. One-third of patients had severe adverse events requiring treatment or dose reduction.

Ignity Inc is currently evaluating RXDX-105 (formerly CEP-32496) in a phase I clinical trial (NCT01877811) in patients with advanced solid tumors with RET or BRAF mutations or rearrangements (Patel *et al.* 2016). Although the trial is mostly intended for lung cancer patients, thyroid cancer patients are eligible to be enrolled as well. The compound was actually described as a poorly selective BRAF inhibitor, with potent off-target activity against RET and other kinases (James *et al.* 2012). Recently, its anti-RET activity was characterized in more detail *in vitro* and *in vivo* (Li *et al.* 2017). The same paper also reports a rapid PR in a NSCLC patient within the ongoing NCT01877811 trial. However, dose reduction was necessary due to toxicity. Indeed, broad inhibitory activity across the kinome of this compound may limit its efficacy in patients.

Next generation of RET targeted drugs

A new wave of RET-specific compounds is coming up in the next few years. By looking at recently filed patent applications, we get the feeling that the RET inhibitor field is about to burst. Likely, the new interest in RET

kinase inhibition has been fostered by the discovery of driver RET mutations in NSCLC and colorectal carcinoma. Although representing a minority of total lung and colon cancer patients (2% and 0.2%, respectively), RET fusion-positive cases are still a numerically important population of individuals (estimated 50,000 new cases per year worldwide), which adds up to the number of RET-positive thyroid cancer patients (about 100,000 per year). Moreover, the dismal prognosis of lung and colon cancers make new targeted treatments very attractive. In contrast, the great majority of thyroid cancers (papillary and follicular types) are characterized by high cure rates, while MTC is a rare disease. With cancer genome sequencing approaching routine use, it is probable that more RET-positive cancer types will be detected in the near future. Hence, RET has entered the stage of 'interesting' molecular targets in oncology. This has spurred a race toward RET-specific drug design programs, from which MEN2 patients will definitely benefit. Here we give a brief overview of forthcoming compounds, as of fall 2017.

Among new anti-RET drugs, BLU-667 of Blueprint Medicines has just started clinical phase I trial in 2017 (NCT03037385). It is claimed to be a potent and selective inhibitor of RET mutations and fusions, including drug-resistant mutants. The candidate was selected from a series of pyridinyl-pyrimidine derivatives, some of which showed low nanomolar activity against the gatekeeper V804L mutant in preclinical *in vitro* studies (Fleming *et al.* 2016, Rahal *et al.* 2016, 2017). The trial will evaluate safety and tolerability of BLU-667 in patients with RET-positive NSCLC and MTC.

GlaxoSmithKline developed two series of compounds specifically designed to inhibit RET kinase in the nanomolar range (Eidam *et al.* 2014, Cheung *et al.* 2016). Their clinical candidates (GSK3352589 and GSK3179106) have recently started phase I, first-in-human, dose escalating controlled studies to evaluate the safety, tolerability and pharmacokinetics in normal healthy volunteers (NCT03154086, NCT02798991 and NCT02727283). Although GSK seems to be developing these compounds for the treatment of irritable bowel syndrome (IBS), they may be as well effective for MEN2 and other RET-driven cancers (Abdel-Magid 2015).

Another interesting family of potential RET inhibitors is represented by quinazoline compounds described by Cancer Research Technology (Goldberg *et al.* 2015, Newton *et al.* 2016). Structurally related to vandetanib, these compounds are shown to possess striking selectivity (>100×) over VEGFR2/KDR kinase, which is a very common co-target of several RET inhibitors, whose inadvertent

inhibition may potentially cause unwanted side effects and confounding anti-angiogenic activity. Therefore, these molecules may have improved therapeutic index compared to current drugs. The key to increased selectivity compared to vandetanib was a change in substituents around the phenyl ring, which also led to improved metabolic and pharmacokinetic features (Newton *et al.* 2016). This family was further elaborated in a more recent work, where the authors identified compounds with improved cellular selectivity (Jordan *et al.* 2016).

Similarly, a very recent patent filed by Array Biopharma claims potent nanomolar RET inhibitors with great selectivity (>30×) vs KDR kinase (Andrews *et al.* 2017). The inventors also propose the use of combinations including their lead compounds and at least one additional agent, to be chosen among known effective drugs for the treatment of cancer and IBS.

Nerviano Medical Sciences (NMS) has launched an ambitious program for the discovery of RET-selective inhibitors (Angiolini *et al.* 2014, Menichincheri *et al.* 2014). Two families of compounds were developed following a common concept of gatekeeper by-pass, shared with ponatinib (see above). In a first series, a triple bond linkage extends from a purine-based core scaffold buried in the active site through binding to the hinge region, bypassing the narrow space around a bulky gatekeeper such as V804M/L mutants of RET. Another recent patent filed by NMS describes compounds with low nanomolar activity and remarkable selectivity for RET+ cells *in vitro*. Again, the compounds are built by a similar design, with an extended linker joining two parts of the molecule, which are likely to fit nicely into the ATP pocket of the kinase even in the presence of large residues at the 804 position. The best compounds from this series are claimed to possess picomolar activity against MTC cells and are currently under preclinical development, with promising activity in RET-driven animal models (Ardini *et al.* 2017).

Dar and colleagues (University of California/Mount Sinai School of Medicine) recently described the discovery of potent RET inhibitors showing a high therapeutic window (Dar *et al.* 2012). Instead of using a classical biochemical screening based on the kinase activity, the authors exploited a *Drosophila in vivo* MEN2B model coupled with genetic and chemical profiling, toward a high-throughput simultaneous readout of target (RET) and anti-target inhibition. This strategy allowed the identification of hit compounds (AD80 and AD81) with the desired activity and devoid of unwanted toxicity. The findings translated into improved *in vivo* efficacy and

tolerability in a mouse xenograft model. Whether this will also hold in humans remains to be demonstrated.

NVP-AST487 is a Flt-3, VEGFR, PDGFR, c-Kit and c-Abl inhibitor with nanomolar activity against RET C634W-transformed NIH3T3 xenografts (Akeno-Stuart *et al.* 2007) and in MEN2-derived human cell lines (Gild *et al.* 2013). It has recently been used to target GDNF-stimulated wild-type RET receptor in MCF7 breast cancer cells, where a role for RET activation in resistance to aromatase inhibitors has been demonstrated (Andreucci *et al.* 2016).

Pz-1 is a very potent compound described by Synactix Pharmaceuticals (Frett *et al.* 2015), which was able to completely suppress RET-driven tumor growth in mice at 1 mg/kg. However, the compound also greatly reduced Ras-induced tumors, which raises doubts on its selectivity and therapeutic applicability. Also, strong VEGFR2 inhibition, as said, may help antitumor activity or cause adverse effects.

To conclude this section, it is worth mentioning that several academic groups, including our lab, have published interesting early phase medicinal chemistry papers describing the discovery of novel RET inhibitors with promising *in vitro* data, in the past three years. Often, efforts were focused on activity against the gatekeeper mutants (Dunna *et al.* 2015, Ferreira *et al.* 2015, Moccia *et al.* 2015, Han *et al.* 2016, Song *et al.* 2016, Yoon *et al.* 2016, 2017, Mologni *et al.* 2017a,b, Wang *et al.* 2017). Finally, in a completely different approach, Kumarasamy and Sun described the selective block of RET transcription by a G-quadruplex-stabilizing agent (Kumarasamy & Sun 2017). By hitting the promoter of RET gene, this strategy would result in suppression of all mutants, but it would not be useful for RET fusions. Similarly, antibody-based approaches such as one described by Takeda (Arai *et al.* 2007) would hit RET mutants expressed on the cell surface, but not fusion oncogenes, that are localized within the cytoplasm. More universal targeting approaches are possible, including antisense, RNAi, or ribozyme-based strategies (Parthasarathy *et al.* 1999, Backman *et al.* 2003). However, all nucleic acid-based therapeutics suffer from poor delivery.

Combination therapies

While targeted cancer monotherapy has demonstrated good efficacy when rationally designed, the combination of two or more agents may further improve the outcome, in an additive or synergistic manner, by causing a more profound anti-tumoral effect. More importantly, combination therapies have the potential of preventing

drug resistance, which very often arises from the selection of pre-existing mutant subclones or from adaptive response to treatment (Gorre *et al.* 2001, Doebele *et al.* 2012, Straussman *et al.* 2012). A few preclinical studies have addressed the issue of combined treatment in MEN2 disease and/or thyroid neoplasia. Lopergolo and colleagues at the National Cancer Institute in Milan, Italy, showed that addition of cisplatin synergistically improved antitumor activity of sunitinib in MTC xenografts, by potentiating the activation of CD95-mediated apoptosis (Lopergolo *et al.* 2014). In another interesting study, sorafenib was shown to cause only transient MAPK pathway inhibition in MTC cell lines at low doses. This led the authors to test whether its effects could be enhanced by concomitant treatment with a MEK inhibitor. Indeed, combination with selumetinib (AZD6244, AstraZeneca) greatly increased growth inhibition compared to either single agent (Koh *et al.* 2012). While this combination has not yet been further investigated in thyroid cancer, the addition of MEK/ERK inhibitors to upstream kinase inhibitors (e.g., BRAF) has proven very successful in other tumors (Robert *et al.* 2015).

The concept of hitting driver oncogenic pathways at multiple nodes was explored by Jin and coworkers (Jin *et al.* 2011). The authors initially sought to block MEK/ERK and PI3K/AKT/mTOR pathways in DTCs driven by RAS, RAF or PTEN mutations. To this end, they combined the dual PI3K/mTOR inhibitor NVP-BEZ235 (Novartis) with the pan-RAF inhibitor RAF265/CHIR-265 (Novartis), which targets VEGFR2 as well. However, they noted that RAF265 is structurally related to sorafenib; hence, it may also block RET kinase. Indeed, the drug was shown to be a potent RET inhibitor and cooperated with BEZ235 to inhibit TT cells (carrying a RET C634W allele) growth *in vivo*. It is possible that VEGFR2 targeting contributed to *in vivo* tumor growth inhibition, similarly to all other effective RET inhibitors. More recently, another group explored synergistic inhibition of RET-mediated signaling and cell growth by the combination of RAF265 with a different PI3K inhibitor, named ZSTK474 (Bertazza *et al.* 2015). ERK and AKT activation, cell growth and survival, and calcitonin expression and secretion were all significantly better inhibited by the combination compared to single treatments, in TT cells.

Another possible strategy may involve the use of heat shock protein inhibitors. As mentioned earlier, pharmacological inhibition of HSP90 by 17-AAG or ganetespib downregulates RET levels in cells (Alfano *et al.* 2010, Lin *et al.* 2017) and sorafenib induces a similar effect after prolonged treatment (Plaza-Menacho *et al.* 2007).

The combination of HSP90 and RET inhibitors may lead to improved block of oncogenic signaling in RET-addicted cells.

A few papers described the use of imatinib (Gleevec, STI-571, Novartis) against RET. However, the drug showed poor activity in preclinical and clinical studies (Cohen *et al.* 2002, de Groot *et al.* 2007). In one attempt to improve its efficacy in MTC models, authors combined imatinib with a FGFR4 inhibitor (PD173074, Ezzat *et al.* 2005). Although the drugs concentrations used *in vitro* were rather high, hardly achievable *in vivo*, the combination did obtain better inhibition of TT xenografts, at reasonable doses.

On the clinical side, a phase I/II trial of vandetanib plus the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) was run in adults with hereditary or sporadic, locally advanced or metastatic MTC. Phase I enrolled 21 patients to find the MTD. Analysis of tumor response in this group showed 29% PR (6/21), while only one patient was enrolled in the phase II and progressed (NCT00923247). A possibly interesting activity of semaxanib (SU5416) in combination with paclitaxel in two metastatic MTC patients remained anecdotal because the compound has then been discontinued. The trial was actually designed for head-and-neck cancers, including thyroid neoplasm, and semaxanib was meant as an anti-angiogenic drug. Interestingly, the only two MTC patients enrolled were among the four patients (out of 11 evaluable) showing prolonged SD (Cooney *et al.* 2005). The documented anti-RET activity of the compound (Mologni *et al.* 2006) may explain these results. A recent single-arm phase 1 trial is currently recruiting patients with advanced cancers, to be treated with a combination of vandetanib plus everolimus, an mTOR inhibitor (NCT01582191). The idea is based on everolimus activity against ABC transporters, which limit drug efficacy, especially in the central nervous system. Indeed, a first successful case has been reported (Subbiah *et al.* 2015). Whether these results will be relevant to the MEN2/MTC population remains to be seen.

Finally, an innovative precision therapy trial (NCT02363647) is inviting patients with sporadic metastatic MTC. After next-generation genetic analysis to identify tumor drivers, a *Drosophila* model is rapidly generated and tested against a panel of FDA-approved drugs or drug combinations, to identify and propose a possible personalized treatment. Time will tell if this strategy will obtain superior response or cure rates compared to current approaches.

Conclusions and future hope

The discovery of RET mutations in MEN2 syndrome 25 years ago opened a new era for the management of the disease. After two decades of intense research, potent RET inhibitors have reached the clinical scene, with many more to come in the next few years (Mologni *et al.* 2017a,b). As physicians know very well, to have a full array of drugs to treat cancer is a most desirable situation, when we are confronted with an enemy that changes rapidly to survive our attacks. However, it is currently unclear what are the mechanisms of primary or acquired resistance to RET inhibitors in thyroid cancer. This information is needed in order to rationally devise effective alternative targeted treatments, as demonstrated for CML patients (Redaelli *et al.* 2012). Surely, RET gatekeeper mutations cause a sharp decrease of efficacy for some drugs *in vitro* (e.g. vandetanib, Carlomagno *et al.* 2004). A recent work reported NRAS mutations in ponatinib-resistant RET-rearranged NSCLC cells (Nelson-Taylor *et al.* 2017). It is also unknown whether sequential targeted therapies with multiple RET inhibitors will improve patients OS. Finally, all current drugs are anti-angiogenic compounds with limited selectivity for RET. Therefore, the relative contribution of anti-RET and anti-VEGFR activities in determining the clinical outcome is not known, although the ZETA trial indicated that RET-positive patients may respond better, suggesting a specific anticancer role for RET inhibition (Wells *et al.* 2012).

It has been an exciting time from the discovery of the target to the development of targeted treatments. Much remains to be done, but we (and Mary) can look forward with new optimism.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

- Abdel-Magid AF 2015 RET kinase inhibitors may treat cancer and gastrointestinal disorders. *ACS Medicinal Chemistry Letters* **6** 13–14. (<https://doi.org/10.1021/ml500402t>)
- Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R & Nutting CM 2011 Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK

- based population. *European Journal of Endocrinology* **165** 315–322. (<https://doi.org/10.1530/EJE-11-0129>)
- Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, et al. 2007 The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. *Cancer Research* **67** 6956–6964. (<https://doi.org/10.1158/0008-5472.CAN-06-4605>)
- Alfano L, Guida T, Provitera L, Vecchio G, Billaud M, Santoro M & Carlomagno F 2010 RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. *Journal of Clinical Endocrinology and Metabolism* **95** 3552–3557. (<https://doi.org/10.1210/jc.2009-2315>)
- Andreucci E, Francica P, Fearn A, Martin LA, Chiarugi P, Isacke CM & Morandi A 2016 Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. *Oncotarget* **7** 80543–80553. (<https://doi.org/10.18632/oncotarget.11826>)
- Andrews SW, Blake JF, Chicarelli MJ, Golos A, Haas J, Jiang Y & Kolakowski GR 2017 *Substituted Pyrazolo[1,5-a]Pyridine Compounds as Ret Kinase Inhibitors*. Array Biopharma, Inc., WO2017011776.
- Angiolini M, Buffa L, Menichincheri M, Motto I, Polucci P, Traquandi G & Zuccotto F 2014 *Pyrrolo[2,3-d]Pyrimidine Derivatives, Process for their Preparation and their Use as Kinase Inhibitors*. Nerviano Medical Sciences, WO2014184069.
- Arai T, Taniyama Y & Kokubo T 2007 *Preventives/Remedies for Cancer*. Takeda Pharmaceutical Company Limited, WO2007049624.
- Ardini E, Banfi P, Avanzi N, Ciomei M, Polucci P, Cirila A, Ermoli A, Motto I, Casale E, Canevari G, et al. 2017 NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models. In *Proceedings of the American Association for Cancer Research Annual Meeting 2017*; Washington, DC. *Cancer Research* 2017 **77** (Supplement 13) abstract 2082. (<https://doi.org/10.1158/1538-7445.AM2017-2082>)
- Atallah V, Hocquet A, Do Cao C, Zerdoud S, De La Fouchardiere C, Bardet S, Italiano A, Dierick-Galet A, Leduc N, Bonichon F, et al. 2016 Activity and safety of sunitinib in patients with advanced radioiodine refractory thyroid carcinoma: a retrospective analysis of 57 patients. *Thyroid* **26** 1085–1092. (<https://doi.org/10.1089/thy.2015.0648>)
- Backman C, Zhang Y, Hoffer BJ & Tomac AC 2003 Short interfering RNAs (siRNAs) for reducing dopaminergic phenotypic markers. *Journal of Neuroscience Methods* **131** 51–56. ([https://doi.org/10.1016/S0165-0270\(03\)00236-X](https://doi.org/10.1016/S0165-0270(03)00236-X))
- Bajpai M 2009 Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. *IDrugs* **12** 174–185.
- Bentzen F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, et al. 2013 In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. *Thyroid* **23** 1569–1577. (<https://doi.org/10.1089/thy.2013.0137>)
- Bertazza L, Barollo S, Radu CM, Cavedon E, Simioni P, Faggian D, Plebani M, Pelizzo MR, Rubin B, Boscaro M, et al. 2015 Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells. *Journal of Cellular and Molecular Medicine* **19** 2244–2252. (<https://doi.org/10.1111/jcmm.12612>)
- Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, et al. 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. *Lancet Oncology* **11** 962–972. ([https://doi.org/10.1016/S1470-2045\(10\)70203-5](https://doi.org/10.1016/S1470-2045(10)70203-5))
- Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, et al. 2014 A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. *Journal of Clinical Endocrinology and Metabolism* **99** 1687–1693. (<https://doi.org/10.1210/jc.2013-3713>)
- Bikas A, Kundra P, Desale S, Mete M, O'Keefe K, Clark BG, Wray L, Gandhi R, Barrett C, Jelinek JS, et al. 2016 Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer. *European Journal of Endocrinology* **174** 373–380. (<https://doi.org/10.1530/EJE-15-0930>)
- Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, Fischer S, Romeo G & Rossi B 1997 The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. *Oncogene* **15** 2257–2265. (<https://doi.org/10.1038/sj.onc.1201413>)
- Borrello MG, Ardini E, Locati LD, Greco A, Licitra L & Pierotti MA 2013 RET inhibition: implications in cancer therapy. *Expert Opinion on Therapeutic Targets* **17** 403–419. (<https://doi.org/10.1517/14728222.2013.758715>)
- Brandhuber B, Haas J, Tuch B, Ebata K, Bouhana K, McFaddin E, Williams L, Winski S, Brown E, Burkhard M, et al. 2016 The development of LOXO-292, a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. In *EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium*. (available at: https://ir.loxooncology.com/docs/presentations/2016_EORTC_LOXO-292_POSTER.pdf)
- Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, et al. 2014 Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet* **384** 319–328. ([https://doi.org/10.1016/S0140-6736\(14\)60421-9](https://doi.org/10.1016/S0140-6736(14)60421-9))
- Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM & Fodstad Ø 2011 Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. *International Journal of Cancer* **129** 742–750. (<https://doi.org/10.1002/ijc.25922>)
- Capdevila J, Carrato A, Tabernero J & Grande E 2014 What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? *Critical Reviews in Oncology/Hematology* **92** 83–106. (<https://doi.org/10.1016/j.critrevonc.2014.05.004>)
- Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. *Cancer Research* **62** 7284–7290.
- Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. *Oncogene* **23** 6056–6063. (<https://doi.org/10.1038/sj.onc.1207810>)
- Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE & Martins RG 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. *Clinical Cancer Research* **16** 5260–5268. (<https://doi.org/10.1158/1078-0432.CCR-10-0994>)
- Cheung M, Demartino MP, Eidam HS, Guan AH, Qin D, Wu C, Gong Z, Yang H, Yu H & Zhang Z 2016 *Novel Compounds as Rearranged during Transfection (ret) Inhibitors*. GlaxoSmithKline, WO2016037578.
- Chow LQ & Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. *Journal of Clinical Oncology* **25** 884–896. (<https://doi.org/10.1200/JCO.2006.06.3602>)
- Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet* **370** 2011–2019. ([https://doi.org/10.1016/S0140-6736\(07\)61865-0](https://doi.org/10.1016/S0140-6736(07)61865-0))

- Clemens GR, Schroeder RE, Magness SH, Weaver EV, Lech JW, Taylor VC, Masuda ES, Baluom M & Grossbard EB 2009 Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. *Birth Defects Research Part A: Clinical and Molecular Teratology* **85** 130–136. (<https://doi.org/10.1002/bdra.20505>)
- Cohen MS, Hussain HB & Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. *Surgery* **132** 960–966; discussion 966–967. (<https://doi.org/10.1067/msy.2002.128562>)
- Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, et al. 2005 A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. *Cancer Chemotherapy and Pharmacology* **55** 295–300. (<https://doi.org/10.1007/s00280-004-0871-5>)
- Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, et al. 2012 Ponatinib in refractory Philadelphia chromosome-positive leukemias. *New England Journal of Medicine* **367** 2075–2088. (<https://doi.org/10.1056/NEJMoa1205127>)
- Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, et al. 2012 Anti-tumor activity of motesanib in a medullary thyroid cancer model. *Journal of Endocrinological Investigation* **35** 181–190. (<https://doi.org/10.3275/7609>)
- Dar AC, Das TK, Shokat KM & Cagan RL 2012 Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. *Nature* **486** 80–84. (<https://doi.org/10.1038/nature11127>)
- Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G & Rischin D 2008 Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. *Anticancer Drugs* **19** 547–552. (<https://doi.org/10.1097/CAD.0b013e3282fc6cf7>)
- De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F & Santoro M 2013 Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. *Journal of Clinical Endocrinology and Metabolism* **98** E811–E819. (<https://doi.org/10.1210/jc.2012-2672>)
- de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ & Voest EE 2007 A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism* **92** 3466–3469. (<https://doi.org/10.1210/jc.2007-0649>)
- Doebele RC, Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, et al. 2012 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clinical Cancer Research* **18** 1472–1482. (<https://doi.org/10.1158/1078-0432.CCR-11-2906>)
- Dunna NR, Kandula V, Girdhar A, Pudutha A, Hussain T, Bandaru S & Nayariseri A 2015 High affinity pharmacological profiling of dual inhibitors targeting RET and VEGFR2 in inhibition of kinase and angiogenesis events in medullary thyroid carcinoma. *Asian Pacific Journal of Cancer Prevention* **16** 7089–7095. (<https://doi.org/10.7314/APJCP.2015.16.16.7089>)
- Edery P, Eng C, Munnich A & Lyonnet S 1997 RET in human development and oncogenesis. *Bioessays* **19** 389–395. (<https://doi.org/10.1002/bies.950190506>)
- Eidam HS, Demartino MP, Gong Z, Guan AH, Raha K, Wu C, Yang H, Yu H, Zhang Z & Cheung M 2014 Pyridine Derivatives as Rearranged during Transfection (ret) Kinase Inhibitors. GlaxoSmithKline, WO2014141187.
- Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V & Kreissl MC 2012 Cabozantinib in progressive medullary thyroid cancer. *Journal of Clinical Oncology* **31** 3639–3646. (<https://doi.org/10.1200/JCO.2012.48.4659>)
- Encinas M, Crowder RJ, Milbrandt J & Johnson EM Jr 2004 Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. *Journal of Biological Chemistry* **279** 18262–18269, Epub 12004 Feb 18206. (<https://doi.org/10.1074/jbc.M400505200>)
- Ezzat S, Huang P, Dackiw A & Asa SL 2005 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. *Clinical Cancer Research* **11** 1336–1341.
- Ferreira R, Nilsson JR, Solano C, Andreasson J & Grotli M 2015 Design, synthesis and inhibitory activity of photoswitchable RET kinase inhibitors. *Scientific Reports* **5** 9769. (<https://doi.org/10.1038/srep09769>)
- Fleming PE, Brooijmans N, Dipietro LV, Kim JL, Wenglowsky SM & Zhang Y 2016 2-(Pyridin-3-yl)-Pyrimidine Derivatives as RET Inhibitors. Blueprint Medicines Corporation, WO2016127074.
- Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, et al. 2013 Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. *Clinical Cancer Research* **19** 4239–4248. (<https://doi.org/10.1158/1078-0432.CCR-13-0071>)
- Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, et al. 2015 Fragment-based discovery of a dual pan-RET/VEGFR2 kinase inhibitor optimized for single-agent polypharmacology. *Angewandte Chemie International Edition in English* **54** 8717–8721. (<https://doi.org/10.1002/anie.201501104>)
- Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, et al. 2014 Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. *Lancet Oncology* **15** 1119–1128. ([https://doi.org/10.1016/S1470-2045\(14\)70362-6](https://doi.org/10.1016/S1470-2045(14)70362-6))
- Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, et al. 2017 Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. *Journal of Clinical Oncology* **35** 1403–1410. (<https://doi.org/10.1200/JCO.2016.70.9352>)
- Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA & Fagin JA 2013 Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. *Endocrine-Related Cancer* **20** 659–667. (<https://doi.org/10.1530/ERC-13-0085>)
- Goldberg K, Hamilton N, Jones S, Jordan A, Lyons A, Newton R, Ogilvie D & Waszkowycz B 2015 *Quinazoline Compounds*. Cancer Research Technology, WO2015079251.
- Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, et al. 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. *Clinical Cancer Research* **13** 1367–1373. (<https://doi.org/10.1158/1078-0432.CCR-06-2328>)
- Goodman KM, Kjaer S, Beuron F, Knowles PP, Nawrotek A, Burns EM, Purkiss AG, George R, Santoro M, Morris EP, et al. 2014 RET recognition of GDNF-GFRalpha1 ligand by a composite binding site promotes membrane-proximal self-association. *Cell Reports* **8** 1894–1904. (<https://doi.org/10.1016/j.celrep.2014.08.040>)
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN & Sawyers CL 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* **293** 876–880, Epub 2001 Jun 2021. (<https://doi.org/10.1126/science.1062538>)
- Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell* **60** 557–563. ([https://doi.org/10.1016/0092-8674\(90\)90659-3](https://doi.org/10.1016/0092-8674(90)90659-3))
- Han M, Li S, Ai J, Sheng R, Hu Y & Geng M 2016 Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET

- kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters* **26** 5679–5684. (<https://doi.org/10.1016/j.bmcl.2016.10.061>)
- Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G & Takahashi M 1997 Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. *Cancer Research* **57** 2870–2872.
- Iwashita T, Asai N, Murakami H, Matsuyama M & Takahashi M 1996 Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. *Oncogene* **12** 481–487.
- Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, et al. 1999 Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. *Oncogene* **18** 3919–3922. (<https://doi.org/10.1038/sj.onc.1202742>)
- James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner ME, Zhao H, Cramer MD, et al. 2012 CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. *Molecular Cancer Therapeutics* **11** 930–941. (<https://doi.org/10.1158/1535-7163.MCT-11-0645>)
- Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH & Ahn SH 2011 Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. *Cancer Biology and Therapy* **12** 458–465. (<https://doi.org/10.4161/cbt.12.5.16303>)
- Jin N, Jiang T, Rosen DM, Nelkin BD & Ball DW 2011 Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. *Clinical Cancer Research* **17** 6482–6489. (<https://doi.org/10.1158/1078-0432.CCR-11-0933>)
- Jordan AM, Begum H, Fairweather E, Fritzl S, Goldberg K, Hopkins GV, Hamilton NM, Lyons AJ, March HN, Newton R, et al. 2016 Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position. *Bioorganic and Medicinal Chemistry Letters* **26** 2724–2729. (<https://doi.org/10.1016/j.bmcl.2016.03.100>)
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, et al. 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *New England Journal of Medicine* **346** 645–652. (<https://doi.org/10.1056/NEJMoa011573>)
- Kato M, Takeda K, Kawamoto Y, Iwashita T, Akhand AA, Senga T, Yamamoto M, Sobue G, Hamaguchi M, Takahashi M, et al. 2002 Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine. *Cancer Research* **62** 2414–2422.
- Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, et al. 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. *Journal of Clinical Endocrinology and Metabolism* **91** 4070–4076, Epub 2006 Jul 4018. (<https://doi.org/10.1210/jc.2005-2845>)
- Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O & Sakamoto H 2014 Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. *Molecular Cancer Therapeutics* **13** 2910–2918. (<https://doi.org/10.1158/1535-7163.MCT-14-0274>)
- Koh YW, Shah MH, Agarwal K, McCarty SK, Koo BS, Brendel VJ, Wang C, Porter K, Jarjoura D, Saji M, et al. 2012 Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. *Endocrine-Related Cancer* **19** 29–38. (<https://doi.org/10.1530/ERC-11-0155>)
- Kumarasamy VM & Sun D 2017 Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative. *International Journal of Oncology* **51** 145–157. (<https://doi.org/10.3892/ijo.2017.3994>)
- Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EEW, Janisch L & Naunberg F 2010 Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. *Journal of Clinical Oncology* **29** 2660–2666. (<https://doi.org/10.1200/JCO.2010.32.4145>)
- Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, et al. 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. *Journal of Clinical Oncology* **28** 2323–2330. (<https://doi.org/10.1200/JCO.2009.25.0068>)
- Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. 2016 Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. *Journal of Clinical Oncology* **34** 1448–1454. (<https://doi.org/10.1200/JCO.2015.63.5995>)
- Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, et al. 2017 Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations. *Clinical Cancer Research* **23** 2981–2990. (<https://doi.org/10.1158/1078-0432.CCR-16-1887>)
- Lin C, Wang S, Xie W, Zheng R, Gan Y & Chang J 2016a Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. *Oncotarget* **7** 59236–59244. (<https://doi.org/10.18632/oncotarget.10985>)
- Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, et al. 2016b Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer. *Journal of Thoracic Oncology* **11** 2027–2032. (<https://doi.org/10.1016/j.jtho.2016.08.126>)
- Lin SE, Lin JD, Hsueh C, Chou TC, Yeh CN, Chen MH & Wong RJ 2017 Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. *Oncotarget* **8** 41294–41304. (<https://doi.org/10.18632/oncotarget.17180>)
- Liu X, Vega QC, Decker RA, Pandey A, Worby CA & Dixon JE 1996 Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. *Journal of Biological Chemistry* **271** 5309–5312. (<https://doi.org/10.1074/jbc.271.10.5309>)
- Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, et al. 2014 Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. *Journal of Clinical Endocrinology and Metabolism* **99** 498–509. (<https://doi.org/10.1210/jc.2013-2574>)
- Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. *Nature Reviews Cancer* **5** 367–375. (<https://doi.org/10.1038/nrc1610>)
- Matsumi J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T & Asada M 2008 E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. *International Journal of Cancer* **122** 664–671. (<https://doi.org/10.1002/ijc.23131>)
- Menichincheri M, Angiolini M, Bertrand JA, Caruso M, Polucci P, Quartieri F, Salom B, Salsa M & Zuccotto F 2014 *Substituted Pyrimidinyl and Pyridinyl-Pyrrolopyridinones, Process for their Preparation and their Use as Kinase Inhibitors*. Nerviano Medical Sciences, WO2014072220.
- Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, et al. 2015 Identification of novel small molecule inhibitors of oncogenic RET kinase. *PLoS ONE* **10** e0128364. (<https://doi.org/10.1371/journal.pone.0128364>)
- Mologni L 2011 Development of RET kinase inhibitors for targeted cancer therapy. *Current Medicinal Chemistry* **18** 162–175. (<https://doi.org/10.2174/092986711794088308>)

- Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, et al. 2006 Inhibition of RET tyrosine kinase by SU5416. *Journal of Molecular Endocrinology* **37** 199–212. (<https://doi.org/10.1677/jme.1.01999>)
- Mologni L, Redaelli S, Morandi A, Plaza-Menacho I & Gambacorti-Passerini C 2013 Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. *Molecular and Cellular Endocrinology* **377** 1–6. (<https://doi.org/10.1016/j.mce.2013.06.025>)
- Mologni L, Dalla Via M, Chilin A, Palumbo M & Marzaro G 2017a Discovery of wt RET and V804M RET inhibitors: from hit to lead. *ChemMedChem* **12** 1390–1398. (<https://doi.org/10.1002/cmdc.201700243>)
- Mologni L, Gambacorti-Passerini C, Goekjian P & Scapozza L 2017b RET kinase inhibitors: a review of recent patents (2012–2015). *Expert Opinion on Therapeutic Patents* **27** 91–99. (<https://doi.org/10.1080/13543776.2017.1238073>)
- Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* **363** 458–460. (<https://doi.org/10.1038/363458a0>)
- Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K & Takahashi M 1999 Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. *Biochemical and Biophysical Research Communications* **262** 68–75. (<https://doi.org/10.1006/bbrc.1999.1186>)
- Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K & Takahashi M 2002 Role of Dok1 in cell signaling mediated by RET tyrosine kinase. *Journal of Biological Chemistry* **277** 32781–32790. (<https://doi.org/10.1074/jbc.M202336200>)
- Nair A, Lemery SJ, Yang J, Marathe A, Zhao L, Zhao H, Jiang X, He K, Ladouceur G, Mitra AK, et al. 2015 FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. *Clinical Cancer Research* **21** 5205–5208. (<https://doi.org/10.1158/1078-0432.CCR-15-1377>)
- Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC & Doebele RC 2017 Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. *Molecular Cancer Therapeutics* **16** 1623–1633. (<https://doi.org/10.1158/1535-7163.MCT-17-0008>)
- Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJR, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, et al. 2016 The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. *European Journal of Medicinal Chemistry* **112** 20–32. (<https://doi.org/10.1016/j.ejmech.2016.01.039>)
- Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, et al. 2013 A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. *Cancer Chemotherapy and Pharmacology* **71** 981–990. (<https://doi.org/10.1007/s00280-013-2091-3>)
- Parthasarathy R, Cote GJ & Gagel RF 1999 Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. *Cancer Research* **59** 3911–3914.
- Patel MR, Fakhri M, Olszanski AJ, Lockhart AC, Drilon AE, Fu S, Bazhenova L, Patel R, Oliver JW, Multani PS, et al. 2016 A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. *Journal of Clinical Oncology* **34** (15 Suppl) 2574. (https://doi.org/10.1200/JCO.2016.34.15_suppl.2574)
- Phay JE & Shah MH 2010 Targeting RET receptor tyrosine kinase activation in cancer. *Clinical Cancer Research* **16** 5936–5941. (<https://doi.org/10.1158/1078-0432.CCR-09-0786>)
- Pinilla-Ibarz J, Cortes J, Kim D-W, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JE, Khoury HJ, Dipersio JE, et al. 2013 Clinical impact of dose modification on response to ponatinib in patients with chronic phase chronic myeloid leukemia. In *ASH Annual Meeting Abstracts. Blood* **122** 4007. (available at: <http://www.bloodjournal.org/content/122/21/4007>)
- Plaza-Menacho I, Barnouin K, Goodman K, Martinez-Torres RJ, Borg A, Murray-Rust J, Mouilleron S, Knowles P & McDonald NQ 2014 Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. *Molecular Cell* **53** 738–751. (<https://doi.org/10.1016/j.molcel.2014.01.015>)
- Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ & Hofstra RM 2006 Current concepts in RET-related genetics, signaling and therapeutics. *Trends in Genetics* **22** 627–636. (<https://doi.org/10.1016/j.tig.2006.09.005>)
- Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D & Isacke CM 2007 Sorafenib functions to potentially suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. *Journal of Biological Chemistry* **282** 29230–29240. (<https://doi.org/10.1074/jbc.M703461200>)
- Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ & Isacke CM 2011 Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. *Journal of Biological Chemistry* **286** 17292–17302. (<https://doi.org/10.1074/jbc.M110.168500>)
- Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, et al. 2005 RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. *Cancer Research* **65** 1729–1737. (<https://doi.org/10.1158/0008-5472.CAN-04-2363>)
- Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, et al. 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potentially inhibits angiogenesis and induces regression in tumor xenografts. *Cancer Research* **66** 8715–8721. (<https://doi.org/10.1158/0008-5472.CAN-05-4665>)
- Quintas-Cardama A & Cortes J 2008 Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. *Clinical Cancer Research* **14** 4392–4399. (<https://doi.org/10.1158/1078-0432.CCR-08-0117>)
- Quintela-Fandino M, Bueno MJ, Lombardia L, Gil M, Gonzalez-Martin A, Marquez R, Bratos R, Guerra J, Tan E, Lopez A, et al. 2014 Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial. *Molecular Oncology* **8** 1719–1728. (<https://doi.org/10.1016/j.molonc.2014.07.005>)
- Raghav KP & Blumenschein GR 2011 Motesanib and advanced NSCLC: experiences and expectations. *Expert Opinion on Investigational Drugs* **20** 859–869. (<https://doi.org/10.1517/13543784.2011.579103>)
- Rahal R, Evans EK, Hu W, Maynard M, Fleming P, DiPietro L, Kim JL, Sheets MP, Wilson DP, Wilson KJ, et al. 2016 The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors. In *American Association for Cancer Research Annual Meeting; New Orleans, LA. Cancer Research* **76** (Supplement 14) abstract 2641. (<https://doi.org/10.1158/1538-7445.AM2016-2641>)
- Rahal R, Maynard M, Hu W, Brubaker JD, Cao Q, Kim JL, Sheets MP, Wilson DP, Fleming P, Wilson KJ, et al. 2017 OP91: BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers. Boston, MA, USA: World Congress on Thyroid Cancer. (available at: <http://thyroidworldcongress.com/presentation/op91-blu-667-is-a-potent-and-highly-selective-ret-inhibitor-in-development-for-ret-driven-thyroid-cancers/>)

- Ravaud A, de la Fouchardiere C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, et al. 2017 A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. *European Journal of Cancer* **76** 110–117. (<https://doi.org/10.1016/j.ejca.2017.01.029>)
- Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D & Gambacorti-Passerini C 2012 Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. *American Journal of Hematology* **87** E125–E128. (<https://doi.org/10.1002/ajh.23338>)
- Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. 2015 Improved overall survival in melanoma with combined dabrafenib and trametinib. *New England Journal of Medicine* **372** 30–39. (<https://doi.org/10.1056/NEJMoa1412690>)
- Robinson BG, Paz-Ares L, Krebs A, Vasselli J & Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. *Journal of Clinical Endocrinology and Metabolism* **95** 2664–2671. (<https://doi.org/10.1210/jc.2009-2461>)
- Robledo M, Gil L, Pollan M, Cebrian A, Ruiz S, Azanedo M, Benitez J, Menarguez J & Rojas JM 2003 Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. *Cancer Research* **63** 1814–1817.
- Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A & Santoro M 2001 Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. *Cancer Research* **61** 1426–1431.
- Santoro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GL, de Francis V & Fusco A 1990 The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. *Oncogene* **5** 1595–1598.
- Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al. 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. *Science* **267** 381–383. (<https://doi.org/10.1126/science.7824936>)
- Schimke RN 1984 Genetic aspects of multiple endocrine neoplasia. *Annual Review of Medicine* **35** 25–31. (<https://doi.org/10.1146/annurev.me.35.020184.000325>)
- Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz J-P, et al. 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. *Journal of Clinical Oncology* **23** 3794–3801. (<https://doi.org/10.1200/JCO.2008.18.7815>)
- Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, et al. 2016 A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. *Clinical Cancer Research* **22** 44–53. (<https://doi.org/10.1158/1078-0432.CCR-15-1127>)
- Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R & Kruijer W 2001 MEN2A-RET-induced cellular transformation by activation of STAT3. *Oncogene* **20** 5350–5358. (<https://doi.org/10.1038/sj.onc.1204715>)
- Scott AJ, Messersmith WA & Jimeno A 2015 Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. *Drugs of Today* **51** 223–229. (<https://doi.org/10.1358/dot.2015.51.4.2320599>)
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licita R, Eschenberg MJ, Sun YN, Juan T, et al. 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. *New England Journal of Medicine* **359** 31–42. (<https://doi.org/10.1056/NEJMoa075853>)
- Song Z, Xia Z, Ji Y, Xing L, Gao Y, Ai J, Geng M & Zhang A 2016 An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core. *European Journal of Medicinal Chemistry* **118** 244–249. (<https://doi.org/10.1016/j.ejmech.2016.04.046>)
- Sonpavde G & Hutson TE 2007 Pazopanib: a novel multitargeted tyrosine kinase inhibitor. *Current Oncology Reports* **9** 115–119. (<https://doi.org/10.1007/s11912-007-0007-2>)
- Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, et al. 2012 Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature* **487** 500–504. (<https://doi.org/10.1038/nature11183>)
- Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, et al. 2015 Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. *Lung Cancer* **89** 76–79. (<https://doi.org/10.1016/j.lungcan.2015.04.004>)
- Sun L, Tran N, Tang F, App H, Hirth P, McMahon G & Tang C 1998 Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. *Journal of Medicinal Chemistry* **41** 2588–2603. (<https://doi.org/10.1021/jm980123i>)
- Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G & Tang C 1999 Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidene]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. *Journal of Medicinal Chemistry* **42** 5120–5130. (<https://doi.org/10.1021/jm9904295>)
- Sun L, Tran N, Liang C, Hubbard S, Tang F, Lipson K, Schreck R, Zhou Y, McMahon G & Tang C 2000 Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. *Journal of Medicinal Chemistry* **43** 2655–2663. (<https://doi.org/10.1021/jm9906116>)
- Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM & Billaud M 1999 Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? *Human Mutation* **13** 331–336. ([https://doi.org/10.1002/\(SICI\)1098-1004\(1999\)13:4<331::AID-HUMU113.0.CO;2-#](https://doi.org/10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU113.0.CO;2-#))
- Vidal M, Wells S, Ryan A & Cagan R 2005 ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. *Cancer Research* **65** 3538–3541. (<https://doi.org/10.1158/0008-5472.CAN-04-4561>)
- Wang C, Liu H, Song Z, Ji Y, Xing L, Peng X, Wang X, Ai J, Geng M & Zhang A 2017 Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors. *Bioorganic and Medicinal Chemistry Letters* **27** 2544–2548. (<https://doi.org/10.1016/j.bmcl.2017.03.088>)
- Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al. 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. *Cancer Research* **62** 4645–4655.
- Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J & Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. *Journal of Clinical Oncology* **28** 767–772. (<https://doi.org/10.1200/JCO.2009.23.6604>)
- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, et al. 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *Journal of Clinical Oncology* **30** 134–141. (<https://doi.org/10.1200/JCO.2011.35.5040>)

- Wells SA Jr, Pacini F, Robinson BG & Santoro M 2013 Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. *Journal of Clinical Endocrinology and Metabolism* **98** 3149–3164. (<https://doi.org/10.1210/jc.2013-1204>)
- Wiegner A, Korb D, Thalheimer A, Kammerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergun S, et al. 2014 E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. *Neoplasia* **16** 972–981. (<https://doi.org/10.1016/j.neo.2014.09.008>)
- Wu H, Shih JY & Yang JC 2015 Rapid response to sunitinib in a patient with lung adenocarcinoma harboring KIF5B-RET fusion gene. *Journal of Thoracic Oncology* **10** e95–e96. (<https://doi.org/10.1097/JTO.0000000000000611>)
- Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al. 2011 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Molecular Cancer Therapeutics* **10** 2298–2308. (<https://doi.org/10.1158/1535-7163.MCT-11-0264>)
- Yoon H, Kwak Y, Choi S, Cho H, Kim ND & Sim T 2016 A pyrazolo[3,4-d]pyrimidin-4-amine derivative containing an isoxazole moiety is a selective and potent inhibitor of RET gatekeeper mutants. *Journal of Medicinal Chemistry* **59** 358–373. (<https://doi.org/10.1021/acs.jmedchem.5b01522>)
- Yoon H, Shin I, Nam Y, Kim ND, Lee KB & Sim T 2017 Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor. *European Journal of Medicinal Chemistry* **125** 1145–1155. (<https://doi.org/10.1016/j.ejmech.2016.10.050>)
- Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB & Chin YE 2004 Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. *Molecular and Cellular Biology* **24** 9390–9400. (<https://doi.org/10.1128/MCB.24.21.9390-9400.2004>)
- Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, et al. 2011 Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. *Chemical Biology and Drug Design* **77** 1–11. (<https://doi.org/10.1111/j.1747-0285.2010.01054.x>)

Received in final form 7 November 2017

Accepted 14 November 2017